[Disclosure] Celltrion Secures European CHMP Recommendation for Marketing Authorization of CT-P47 (068270)

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-12-16

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion’s Actemra biosimilar ‘CT-P47’ has obtained a positive opinion recommending marketing authorization for 30 European countries from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA), leaving only the final official approval from the European Commission (EC).

📊 1. [Key Disclosure Content & Major Financial Figures Summary]

• Target Product: Actemra biosimilar CT-P47 (Ingredient: Tocilizumab)
• Indications (Target Diseases): All indications approved for the original product, including:
  • Rheumatoid Arthritis
  • Giant Cell Arteritis
  • Systemic Juvenile Idiopathic Arthritis
  • Juvenile idiopathic polyarthritis
  • Cytokine Release Syndrome
  • Coronavirus Disease 2019 (COVID-19)
• Key Schedule (Local Time):
  • Application Date: February 8, 2024
  • Date of CHMP Recommendation: December 12, 2024 (Fact confirmation date: December 13, 2024)
  • Approving Authority: Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)
• Scope of Recommendation: Approval recommended for marketing across 30 European countries.
• Expectations & Plans: The recommendation covers all indications held by the reference product, and Celltrion expects to secure final marketing authorization from the European Commission (EC) in the near future following this CHMP positive opinion.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This filing represents a formal regulatory milestone where CT-P47 has cleared the primary scientific evaluation body (CHMP), which is the practical final hurdle prior to commercial launch in the European market. This milestone was reached approximately 10 months after the initial application on February 8, 2024.

However, investors should note that the current status is a “recommendation” rather than the “final marketing authorization” from the European Commission (EC). Although the company states that it expects to secure final approval in the near future, the exact timing and final decision remain subject to the EC’s administrative procedures. Furthermore, even after securing the final approval, the actual timing of commercialization, national pricing registrations, and launch schedules will determine when tangible revenue begins to accrue. Investors should approach this stage cautiously, recognizing it as a positive recommendation pending final executive authorization.

📝 Editor’s Comment (by K-STOCK Editor)

This CHMP recommendation serves as the direct administrative outcome of the “European Marketing Authorization Application” disclosed on February 13, 2024. The essential fact is that the positive opinion was granted for all six indications of the reference product, including Rheumatoid Arthritis and COVID-19.

It is critical to distinguish this positive opinion from the actual permission to commercialize the drug. Legally, commercial sales can only commence after the European Commission (EC) conducts its review and issues the final formal Marketing Authorization. This disclosure does not outline concrete commercialization schedules, expected pricing, or projected sales figures.

Consequently, the key objective checkpoint for investors moving forward is the official publication of the “Final Marketing Authorization Approval” from the European Commission (EC). Verifying that this final administrative step is finalized without unexpected delays is the necessary baseline for evaluating any future impact on corporate value.

📢 Disclaimer & Source Information

Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.